| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CHRNa3 |
| Uniprot No | P32297 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 32-240aa |
| 氨基酸序列 | SEAEHRLFERLFEDYNEIIRPVANVSDPVIIHFEVSMSQLVKVDEVNQIMETNLWLKQIWNDYKLKWNPSDYGGAEFMRVPAQKIWKPDIVLYNNAVGDFQVDDKTKALLKYTGEVTWIPPAIFKSSCKIDVTYFPFDYQNCTMKFGSWSYDKAKIDLVLIGSSMNLKDYWESGEWAIIKAPGYKHDIKYNCCEEIYPDITYSLYIRRL |
| 预测分子量 | 44.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CHRNa3重组蛋白的3篇示例参考文献(内容为模拟概括，仅供参考)：
1. **文献名称**：Functional characterization of recombinant CHRNA3 in nicotine receptor signaling
**作者**：Smith JL, et al.
**摘要**：研究通过HEK293细胞表达重组CHRNa3蛋白，结合电生理学分析，发现其与β4亚基共表达时形成功能性尼古丁乙酰胆碱受体，介导钙离子内流，可能与尼古丁成瘾相关。
2. **文献名称**：CHRNA3 polymorphisms and COPD risk: Role of recombinant protein in airway inflammation
**作者**：Wang H, et al.
**摘要**：构建重组CHRNa3蛋白并用于体外炎症模型，发现特定基因突变(如rs1051730)导致蛋白构象改变，增强IL-8分泌，提示CHRNa3异常可能通过炎症通路促进慢性阻塞性肺病发展。
3. **文献名称**：Purification and structural analysis of human CHRNA3 extracellular domain
**作者**：Garcia-Rojas M, et al.
**摘要**：利用杆状病毒系统表达重组CHRNa3胞外域蛋白，经晶体学解析发现其α螺旋结构域与尼古丁结合的关键位点，为靶向药物设计提供结构基础。
**注意**：以上为模拟示例，实际文献请通过PubMed/Google Scholar检索关键词(如“CHRNA3 recombinant protein”、“CHRNA3 expression and function”)。
The CHRNA3 recombinant protein is derived from the CHRNA3 gene, which encodes the alpha-3 subunit of neuronal nicotinic acetylcholine receptors (nAChRs). These receptors are ligand-gated ion channels involved in synaptic transmission, particularly in the autonomic nervous system, brain regions linked to addiction, and neuroendocrine functions. The α3 subunit combines with β subunits (e.g., β4) to form functional receptor complexes that mediate cholinergic signaling. CHRNA3 variants are clinically associated with nicotine dependence, lung cancer susceptibility, and chronic obstructive pulmonary disease (COPD), making it a focal point for translational research.
Recombinant CHRNA3 protein is typically produced in heterologous expression systems (e.g., mammalian cells or bacteria) to ensure proper folding and post-translational modifications. It retains structural and functional properties of the native protein, enabling studies on receptor assembly, ligand binding, and downstream signaling. Researchers utilize this protein to investigate interactions with nicotine, acetylcholine, or therapeutic compounds, as well as to map epitopes for antibody development. Its applications extend to drug screening platforms targeting nAChR-related disorders, including addiction therapies and cancer biomarker studies.
In disease contexts, CHRNA3’s role in nicotine reward pathways and cell proliferation mechanisms highlights its dual relevance in neurobiology and oncology. Recombinant forms facilitate mechanistic studies, such as how specific mutations alter receptor kinetics or contribute to disease risk. Additionally, it serves as a critical tool for validating genetic associations identified in genome-wide studies, bridging genetic data with molecular pathophysiology. Overall, CHRNA3 recombinant protein is indispensable for dissecting cholinergic signaling complexities and advancing targeted therapies for nAChR-associated diseases.
×
